The COVID-19 pandemic has had a heavy impact on global health and economy and vaccination remains the primary way of controlling the infection. During the ongoing vaccination campaign some unexpected thrombotic events have emerged in subjects who had recently received the AstraZeneca (Vaxzevria) vaccine or the Johnson&Johnson (Janssen) vaccine, two adenovirus vector-based vaccines. Epidemiological studies confirm that the observed/expected ratio of these unusual thromboses is abnormally increased, especially in women in fertile age. The characteristics of this complication, with venous thromboses at unusual sites, most frequently in the cerebral vein sinuses but also in splanchnic vessels, often with multiple associated thromboses, thrombocytopenia, and sometimes disseminated intravascular coagulation, are unique and the time course and tumultuous evolution are suggestive of an acute immunological reaction. Indeed, platelet-activating anti-PF4 antibodies have been detected in a large proportion of the affected patients. Several data suggest that adenoviruses may interact with platelets, the endothelium and the blood coagulation system. Here we review interactions between adenoviral vectors and the hemostatic system that are of possible relevance in vaccine-associated thrombotic thrombocytopenia syndrome. We systematically analyze the clinical data on the reported thrombotic complications of adenovirus-based therapeutics and discuss all the current hypotheses on the mechanisms triggering this novel syndrome. Although, considering current evidence, the benefit of vaccination clearly outweighs the potential risks, it is of paramount importance to fully unravel the mechanisms leading to vaccine-associated thrombotic thrombocytopenia syndrome and to identify prognostic factors through further research.

Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome

Paolo Gresele,1 Stefania Momi,1 Rossella Marcucci,2 Francesco Ramundo,3 Valerio De Stefano1 and Armando Tripodi4

1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia; 2Department of Experimental and Clinical Medicine, University of Florence; Atherothrombosis Center, AOI Careggi, Florence; 3Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome and 4Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

ABSTRACT

Introduction

The COVID-19 pandemic has prompted an unprecedented effort to develop highly effective vaccines to prevent further spreading of the infection, the associated mortality and the enormous strain on healthcare systems. Indeed, in a previously unimaginable short time, many vaccines have been developed. Several of them underwent controlled randomized phase III clinical trials and, as of 22 June, 2021, 13 have been licensed globally for clinical use. By July 18, 2021 they had been administered to more than 1.9 billion subjects worldwide (923 million of whom are fully vaccinated; 3.66 billion doses have been administered globally; 26.3% of the world’s population has received at least one dose of a COVID-19 vaccine). This represents the most massive vaccination campaign ever undertaken...
Adenoviruses, platelets and the blood coagulation system

Based on available data and given that VITT has been associated with Ad-vector-based vaccines, hypotheses on a direct role of the interaction between Ad and blood components can be made.

Ad are non-enveloped DNA viruses with a nucleoprotein core encapsulated by an icosahedral protein capsid from which proteinaceous fibers protrude. The C-terminal knob domain at the distal end of these fibers is responsible for virus binding to its primary cellular receptor, a 46-kDa transmembrane protein1,12 which also functions as a receptor for Coxsackie B virus and is, therefore, called coxsackie and Ad receptor (CAR).13-15 The high affinity binding of Ad to CAR starts receptor-mediated endocytosis.16 Moreover, Ad have evolved other mechanisms to facilitate cell entry via recognition of the arginine-glycine-aspartate (RGD) sequence on cell surface integrins. Molecules expressed on host cell surfaces involved in cell infection include the vitronectin-binding integrins αvβ3 and αvβ5, the fibronectin-binding integrin αvβ3, and others, such as αvβ3, all characterized by a common RGD peptide sequence which is recognized by the RGD ligand in the HI fiber knob loop of the Ad penton base protein. Although the CAR is expressed in almost all tissues, including the adult nervous system and cerebral vasculature,22,23 muscle,24 heart25 and the hematopoietic system,26 its presence in platelets is debated. Othman et al.16 identified CAR (by flow cytometry) and its mRNA (by reverse transcriptase polymerase chain reaction) in human platelets27 while Shimony et al.15 did not confirm the presence of the receptor and proposed that binding of Ad to platelets is mediated by an interaction between RGD-binding motifs of Ad and platelet αvβ3 (Figure 1).

Indeed, human megakaryocytes either do not express mRNA for CAR or express it at extremely low levels (J. Rowley and A.S. Weyrich, University of Utah, personal communication). After intravenous inoculation in mice, Ad rapidly bind circulating platelets causing their activation and subsequent entrapment in liver sinusoids where virus-platelet aggregates are taken up by Kupffer cells and degraded. Platelet activation is followed by activation of blood coagulation, leading to DIC.28-30 Activated platelets also release cytokines promoting endothelial cell activation with secretion of von Willebrand factor, binding of platelets to endothelial cells and the formation of platelet/leukocyte aggregates, eventually triggering the development of microthrombi in liver sinusoids.21,22 There is also a complex interplay between Ad and the coagulation system. In fact, the distribution and activity of Ad in blood is affected by interactions with plasma proteins, including complement and vitamin K-dependent coagulation factors, which act as opsonizing agents. Our knowledge of these interactions derives mainly from in vitro observations and it is unknown whether the interplay of Ad with coagulation proteins affects the activity of the latter. Vitamin K-dependent coagulation factors, including the anticoagulant protein C, interact with Ad-5, the most widely used Ad vector. Activated protein C is generated on endothelial cells via the interaction of protein C with the thrombin-thrombomodulin complex and the endothelial protein C receptor (EPCR). Activated protein C requires protein S to express anticoagulant activity.31 Protein S circulates either free or associated with C4BP, a
regulatory protein of the complement system. C4BP binds to activated platelets through mechanisms involving chondroitin sulfate expressed on activated platelets and to membrane-associated protein S on platelets. Interestingly, the protein C anticoagulant pathway plays a peculiar pathophysiological role in CVST. Small but measurable amounts of EPCR are also found in plasma. Soluble EPCR binds both protein C and activated protein C with an affinity similar to that of membrane-bound EPCR but, in contrast to the latter, it inhibits activated protein C anticoagulant activity thus limiting its ability to inactivate activated factor V, and also binds protein C impeding its activation by thrombin-thrombomodulin complexes. An increase in soluble EPCR was observed in CVST, possibly leading to a procoagulant condition and enhanced risk of thrombosis. Finally, Gas6 (encoded by the growth arrest-specific 6 gene), a vitamin K-dependent protein with 44% sequence homology with protein S but devoid of anticoagulant activity, is widely expressed in the cerebral nervous system where it is found on resting endothelial cells. Gas6 potentiates platelet activation acting on Tyro3, Axl and Mer (TAM) receptors leading to thrombus formation and in vitro studies have shown that Gas6 binds to Ad enhancing their gene expression.

The affinity of different Ad for coagulation factors is variable, with a considerable number of Ad types unable to bind them. Ad-5, Ad-2 and Ad-16 bind strongly to factor X. Moreover, the ability of Ad to bind coagulation factors is species-specific, e.g., Ad-5 binds human and mouse factor X with similar affinity, but Ad-2 binds human factor X with 10-fold lower affinity than mouse factor X. Vitamin K-dependent coagulation factors VII, IX, X, and protein C mediate the binding of Ad to hepatocytes. For instance, for Ad-5 hepatotropism is critically dependent on the ability of the Ad-5 hexon to bind factor X. In contrast, non-factor X-binding Ad, such as Ad-48 and Ad-26, do not show hepatocyte tropism. The primary reason why factor X is required for Ad-5 transduction to the liver is that it protects Ad-5 from attack by complement. It has been previously ascertained that components of intramuscularly-injected vaccines, including the Ad vector, are disseminated in the circulation and it is thus conceivable that some of the above described activating interactions between Ad and platelets, endothelium and the blood clotting system can occur in recipients of Ad-vector-based vaccines. However, so far no experimental evidence that this may have a role in VITT is available and actually it seems unlikely that sufficiently high circulating levels of a non-replicating Ad vector may be reached to trigger platelet activation or blood coagulation changes. In fact, it should be considered that around 2,500 billion virions/kg are required to trigger this reaction in mice and non-human primates, and even if all the Vaxzevria viral content were to spill-over into the blood after intramuscular administration, a concentration of 0.7 billion/kg Ad viral vectors would be reached, which is probably insufficient to activate platelets/coagulation.

**Antibody-dependent enhancement and vaccine-associated adverse events**

Antibody-dependent enhancement (ADE) is an immunological form of a more general phenomenon called enhanced respiratory disease, leading to the clinical worsening of respiratory viral infections. ADE can occur either through an antibody-mediated increase of virus uptake by Fcy receptor IIa (FcRIIa)-expressing phagocytic cells, thus facilitating viral infection and replication, or by boosting immune activation through excessive Fc-mediated immunological cell effector functions or immune responses. This can result in increased viral load, tissue damage, and adverse outcomes. The mechanism involves the interaction of viral particles with antibody-coated receptors on immune cells, leading to increased viral entry and replication. Antibody-dependent enhancement is a concern in the development of vaccines, as it can lead to enhanced disease in recipients.

---

**Figure 1. Hypothesized interactions between platelets and adenoviruses.** Adenoviruses (Ad) induce platelet activation either by binding to platelet coxsackie and adenovirus receptor (CAR) or to platelet-surface integrins, such as αvβ3 or α5β1. Moreover, circulating Ad-elicted IgG or immune complexes may directly activate platelets through FcRIIa. Gas6 exposed by cerebral vein endothelial cells may bind Ad and activate platelets acting on Tyro3, Axl and Mer (TAM) receptors. Ad may also bind CAR expressed by cerebral vein vessels in this way activating endothelial cells which in turn may elicit platelet activation.
complex formation with consequent increase of inflammation and immunopathology. Both ADE pathways can occur when non-neutralizing antibodies or antibodies at sub-neutralizing levels bind to viral antigens without blocking or clearing the infection. ADE has been reported for vaccines against both severe acute respiratory syndrome corona virus (SARS-CoV) and Middle East respiratory syndrome corona virus (MERS-CoV) in vitro and in animal models. The cytoplasmic tail of FcγRIIA activates the protein-tyrosine kinases Src and Syk. Src-dependent signaling has been shown to be crucial for ADE triggered by Ebola virus, enhancing viral uptake into cells and thus worsening the infection.

Circulating antibodies activating platelet IgG FcγRIIA may be key determinants of a host response leading to uncontrolled platelet aggregation and thrombosis. Studies in transgenic mice expressing human FcγRIIA on platelets showed that the administration of anti-CD9 antibodies caused thrombosis accompanied by platelet consumption, a response that was absent in mice lacking the receptor. The clinical relevance of this pathway for thrombotic disorders in humans is confirmed by the observation that FcγRIIA expression is higher in patients with stroke and that relatively common FcγRIIA polymorphisms are associated with increased risk of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Immuno-complex formation, complement deposition and local immune activation are likely mechanisms triggered by SARS-CoV-2 vaccine. Furthermore, pre-existing antibodies to coronavirus strains endemic in humans could mediate ADE by facilitating cross-reactive recognition of SARS-CoV-2 in the absence of viral neutralization.

Interestingly, compared to Ad-5 and Ad-6, chimpanzee adenoviruses (ChAd) are much less frequently neutralized by pre-existing antibodies present in humans. The prevalence of vector-neutralizing antibodies against Y25, now renamed ChAdOx1, the vector of the Vaxzevria vaccine, in human sera from British and Gambian adults was found to be 0% (n=100) and 9% (n=57), respectively. The presence of these antibodies in rare patients in Europe might theoretically represent one potential mechanism triggering ADE, and possibly VITT, in vaccine recipients but no data on this are available yet.

Despite the above hypotheses, preliminary in vitro evidence suggests that serum from convalescent COVID-19 patients does not induce either enhancement of SARS-CoV-2 infection or innate immunity responses in human macrophages, indicating that ADE may not be involved in the immune-pathological processes associated with COVID-19 infection or immunization.

Use of adenovirus vectors and thrombotic events

Adenovirus vectors for gene therapy
Ad vectors have been used therapeutically for their ability to transduce and deliver transgenes to different cell types. However, for these indications the clinical use of Ad vectors has been limited to a few tens of patients and the main concerns have been the development of humoral and cellular immunity occurring upon repeated administration and/or the possible neutralization of the vector by pre-existing immunity against the virus, while little attention had been paid to the possible interactions of Ad vectors with platelets and the blood clotting system.

The first use of Ad vectors for gene therapy of inherited disorders or to treat neoplasia dates back to the 1990s. An analysis of the risks associated with the use of Ad-vectored gene therapies among 90 individuals who received 140 administrations for various diseases (cystic fibrosis, metastatic colorectal cancer, cardiovascular disease), showed that 13 deaths were recorded. The authors concluded that none was linked to the Ad vector. The reported hematologic abnormalities were decreased hemoglobin, leukocytosis, thrombocytopenia, and prolongation of the activated partial thromboplastin time (aPTT), with no cases of DIC.

It is, however, puzzling that a recently European Medicines Agency-licensed Ad-vectored gene therapy for spinal muscular atrophy received a warning about the possible risk of thrombotic microangiopathy based on the reporting of five cases in treated infants (https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma).

Adenovirus-vectored vaccines
Beside SARS-CoV-2, Ad vectors have been used for the preparation of other vaccines, including the ChAdOx1-vectored vaccines for MERS-CoV and Chikungunya; with only a few hundred volunteers having received these vaccines up to June 2020, no excess of thrombotic events had been noted. Even for the Ebola vaccination campaign, the largest previous example of large-scale vaccination using an Ad vector, a maximum of around 200,000 volunteers were treated, with only one venous thrombosis reported (Table 1). However, it may be extremely difficult to prove that adverse events following immunization are caused by the vaccine itself when their occurrence is extremely rare (https://www.nature.com/articles/d41586-021-00880-9. Accessed on April 9, 2021).

Except for common mild/moderate reactome reactions, the most frequently recorded adverse events in clinical trials were hematologic (e.g., mild hemoglobin decrease, thrombocytopenia, leukopenia) the majority of which recovered a few days or weeks after vaccination. The extent and rate of hematologic adverse events associated with Ad-vectored vaccines are summarized in Table 1. Occasional abnormalities of coagulation were reported, with prolongation of the aPTT, possibly due to the development of transient antiphospholipid antibodies. Thrombotic events were rare both for human and non-human Ad-vectored vaccines. One case of phlebitis was observed among 114 volunteers who received a recombinant, replication-defective Ad-5-vectored vaccine expressing human immunodeficiency virus (HIV)-1 antigenic proteins. Another case of deep vein thrombosis was observed among 58 volunteers after administration of a recombinant, replication-defective Ad-35-vectored vaccine expressing HIV-1 antigens. Both events were considered unrelated to the vaccine.

A systematic review identified 200 clinical studies on active immunization against SARS-CoV-2. The second most used vaccine platform, after mRNA-based vaccines, was represented by Ad vectors (24%). Concerning chimpanzee Ad-vectored vaccines (ChAdOx1 nCoV-19), neutropenia was the most common hematologic abnormality (Table 1). Across all studies, vaccines had a good
| Adenoviral Vector | Pathogens | Study (type of) | N. of participants | Thrombocytopenia (n) | Venous thromboembolism (n) | Coagulation disorders | Other hematologic complications | Other systemic adverse events |
|------------------|-----------|----------------|-------------------|---------------------|---------------------------|---------------------|-------------------------------|-----------------------------|
| **Chimpanzee Adenovirus** | Influenza A | Phase I, dose-escalation (S1) | 15 | NR | NR | NR | Leukopenia | Fatigue, malaise, headache |
| | MERS | Phase I, dose-escalation, non-randomized, uncontrolled (S4) | 24 | NR | NR | NR | Anemia, neutropenia | Fatigue, headache, malaise, myalgia |
| | SARS-CoV-2 | Phase VII, single-blind, randomized, controlled (70) | 1077 | NR | NR | NR | Neutropenia | Fatigue, headache |
| **ChAd3** | Ebola | Phase I, dose-escalation, open-label (S2) | 20 | NR | NR | aPTT prolongation (15%) | Leukopenia | Fever |
| | | Phase IIa, double-blind, placebo-controlled, dose-finding (S3) | 120 | NR | NR | aPTT prolongation (n=1) | Anemia, lymphopenia, neutropenia | Fatigue, headache, myalgia |
| | | Phase I, dose-escalation, open-label (S4) | 60 | 1 | NR | aPTT prolongation (n=4) | Leukopenia, eosinophilia | Fatigue, headache, myalgia |
| | | Phase II, randomized, observer-blind, placebo-controlled (S5) | 3030 | 7 | Vera cava thrombosis (n=1) | NR | Anemia | Fever |
| | | Phase II, randomized, observer-blind, placebo-controlled (S6) | 600 | 5 | NR | NR | Anemia | Fever |
| | RSV | Phase I, open-label, single-site, dose-escalation (S7) | 42 | 2 | NR | NR | Anemia | Fatigue, headache, myalgia, nausea |
| **Human Adenovirus** | HIV | Phase I, double-blind, randomized, placebo-controlled (66) | 114 | NR | Phlebitis (n=1) | NR | Leukopenia, anemia | Fatigue, malaise, headache |
| | | Phase I, double-blind, placebo-controlled (S8) | 36 | NR | NR | NR | Neutropenia | Fever, malaise, myalgia, chills |
| | | Phase III, double-blind, randomized, controlled (S9) | 801 | NR | NR | NR | Neutropenia, anemia | Headache, malaise, myalgia |
| | Ad5 | Ebola | Phase I, randomized, double-blind, placebo-controlled (S10) | 120 | NR | NR | NR | Anemia, leukopenia | Fever |
| | | Phase I, single-site, double-blind, randomized, placebo-controlled, dose-escalation (S11) | 32 | NR | NR | aPTT prolongation (n=2) | NR | Malaise, myalgia, headache, chills |
| | | Phase I, single-centre, dose-escalation, double-blind, non-randomized (S12) | 108 | 4 | NR | NR | NR | Fever, fatigue, headache, muscle pain |
| | SARS-CoV-2 | Phase III, randomized, double-blind, placebo-controlled (71) | 44325 | NR | DVT (n=6), PE (n=4), CSVT (n=1) | NR | NR | Fatigue, headache, myalgia, nausea |
| | Ad26 | Ebola | Phase II, randomized, double-blind, placebo-controlled (S13) | 423 | NR | NR | NR | Anemia, neutropenia | Fatigue, headache, myalgia, chills |
| | HIV | Phase I, double-blind, randomized, placebo-controlled (67) | 58 | NR | DVT (n=1) | NR | NR | Malaise, myalgia, headache, chills |
| | Plasmodium Falciparum | Phase I, randomized, double-blind, dosage-escalation (S14) | 48 | 1 | NR | NR | WBC count abnormalities | Myalgia, chills, headache, fever, vomiting |
| | | Phase I, randomized, placebo-controlled, dose-escalation (S15) | 72 | NR | NR | NR | Neutropenia, eosinophilia | Fever, headache, malaise, myalgia, nausea |
| | Ad26-Ad35 | SARS-CoV-2 | Phase III, non-randomized, single-center (72) | 21977 | NR | DVT (n=1) | NR | NR | Fever, headache, fatigue, myalgia |

The reference numbers preceded by an S refer to references listed in the Online Supplementary Material. The adverse events reported are related only to the vaccinated groups and not to the placebo groups. MERS: Middle East respiratory syndrome virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RSV: respiratory syncytial virus; HIV: human immunodeficiency virus; NR: not reported; DVT: deep vein thrombosis; PE: pulmonary embolism; CSVT: cerebral sinus versus thrombosis; aPTT: activated partial thromboplastin time; WBC: white blood cell.
safety profile with no difference in severe reactions between study arms. In a phase III trial with a recombinant, replication-incompetent human Ad-26 vector encoding the SARS-CoV-2 spike protein, with 43,783 participants, 11 venous thromboembolic events were observed in the vaccine group compared to three in the placebo group (Table 1); however, most subjects had underling medical conditions that might have contributed to these events. In the vaccine group there were six cases of lower leg deep venous thrombosis and four cases of pulmonary embolism. Interestingly, however, a CVST, with cerebral hemorrhage and thrombocytopenia, occurred 21 days after vaccination in a 25-year-old male who had multiple predisposing factors, including pre-existing cerebral sigmoid sinus stenosis and infection from an unknown pathogen. Subsequent testing identified anti-PF4 antibodies at the time of the event. The patient recovered.

In a phase III controlled randomized clinical trial with a recombinant Ad-26-vectored and a recombinant Ad-5-vectored vaccine (Sputnik V) among 16,501 participants, ten vascular events (0.061%) were observed including: one deep vein thrombosis (0.006%), one transient ischemic attack (0.006%), one cerebral circulation failure (0.006%), one vascular encephalopathy (0.00659%) and two acute myocardial infarctions (0.012%) (4 additional events were non thrombotic) (Table 1).

The vaccine-induced immune thrombocytopenia syndrome

When the anti-SARS-CoV-2 vaccination campaign was well underway worldwide a few cases of spontaneous, severe thromboembolic events in otherwise healthy subjects began to be reported, leading to a pause in the administration of the Vaxzevria vaccine in several European countries (https://www.ema.europa.eu/en/news/emas-safety-committee-continues-investigation-covid-19-vaccine-astrazeneca-thromboembolic-events). Soon after several case reports were published, mainly concerning young females, with new ones continuing to accrue, although many were not subject to rigorous central review and with anti-PF4 antibodies measured using disparate methods, not allowing to conclude that all were typical VITT cases.

Up to July 17, 2021, 105 such cases with two Ad-vectored vaccines had been published (Table 2) with some common clinical features characterizing a new syndrome, including thrombocytopenia, often severe, venous thrombosis at unusual sites, in particular of the cerebral sinuses but also of the splanchic veins, frequently associated with thromboses in multiple sites, both venous and arterial, and sometimes DIC combined with hemorrhage. A comparative evaluation of the clinical characteristics of the published ChAdOx1 or Ad26.CoV2.S VITT cases suggests that while clinical symptoms are comparable, Ad26.CoV2.S-associated cases show more thrombosis and intracerebral hemorrhage, lower D-dimer and less altered aP TT, but a similar mortality. In a recent, large nationwide healthcare register-based study in Denmark and Norway involving 281,264 ChAdOx1-S-vaccinated subjects aged 18-65 and as controls the entire age-matched populations of the two countries studied in the period 2016-2019, the standardized morbidity ratio for CVST was 20.25 (8.14-41.7), with an excess of 2.5 events per 100,000 vaccinations, particularly evident in women 18-44 years old, confirming the crucial relationship between Vaxzevria administration and occurrence of VITT. The catastrophic syndrome, burdened by a 20-50% mortality rate, has the time course and tumultuous evolution of an acute immunological reaction and indeed three groups of investigators identified, in several of their patients, circulating antibodies to PF4/heparin complexes using an enzyme-linked immunosorbent assay (ELISA) and a heparin-induced platelet activation assay, and thus proposed that this disorder is a peculiar form of autoimmune HIT.

The autoimmune heparin-induced thrombocytopenia hypothesis

HIT is a rare immune-mediated adverse drug reaction that may occur after exposure to heparin. Circulating heparin binds to PF4, a positively charged platelet protein released in plasma upon activation. PF4 normally binds to negatively charged glycosaminoglycans on the endothelium, displacing antithrombin and thus activating coagulation. However, PF4 binds with greater affinity to heparin, forming heparin/PF4 complexes which become neoantigens inducing the formation of autoantibodies. Heparin-PF4-IgG immune complexes in turn bind to platelet FcγRIIA receptors causing activation, aggregation, and additional release of PF4, with formation of a positive feedback loop leading to further platelet activation and consumption. Moreover, these complexes also activate monocytes, which release tissue factor, thus promoting concomitant activation of coagulation.

HIT is a potentially fatal condition, associated with the development of arterial or venous thrombosis. Thrombocytopenia occurs in more than 85% of HIT patients and is usually of moderate severity, with median platelet counts of approximately 50-60×10^9/L, although values <20×10^9/L can be found in approximately 10% of cases. Typically, the platelet count starts to decrease 5-10 days after initiation of heparin, but early-onset thrombocytopenia (rapid-onset), within 24 h of exposure, can develop in 25-30% of cases if patients have been treated with heparin in the preceding 3 months. Thromboembolic complications occur in 35-75% of HIT patients and are usually severe. They can be venous (i.e., deep vein thrombosis and pulmonary embolism, but rarely also CVST or splanchnic thrombosis), arterial (ischemic stroke, myocardial infarction, acute occlusion of limb arteries) or microvascular (digital infarction).

Recently, another clinical picture not triggered by exposure to heparin has been recognized and defined as autoimmune HIT. The main characteristic of this condition is the presence of circulating antibodies able to activate platelets also in the absence of heparin. Polyanion molecules potentially involved in the development of autoimmune HIT are typically bacteria and virus components, hypersulfated chondroitin sulfate, DNA and RNA and polyphosphates. Patients with this syndrome show slightly different clinical features from those with classical HIT, including severe thrombocytopenia (<20×10^9/L), sometimes in combination with DIC, microvascular thrombosis and CVST in up to 40% of cases. From a therapeutic standpoint, besides the indication for an alternative anticoagulant, valid also for HIT, the intravenous
administration of high doses of IgG in combination with steroids has been proposed for autoimmune HIT.

Very early after the first reports of unusual types of thrombosis associated with the Vaxzevria vaccine, a German group suggested a tentative pathogenic mechanism underlying these rare events, which they named VIPIT, based on findings in nine cases of previously vaccinated subjects. Indeed, in sera from four of these subjects the investigators detected antibodies to PF4/heparin complexes using an enzyme-immunoassay; these antibodies were inhibited by the addition of high concentrations of heparin (i.e., 100 U/mL), and the sera were able to activate washed control platelets when either PF4 or the Vaxzevria vaccine was added in vitro to the samples.

| Vaccine     | VITT cases, n | Female, n (%) | Age range, years | CVST, n/total | Platelet count nadir-range x10^9/L | Negative anti PF4, n (total) | Heparin-treated with success, n/treated | Time form vaccination range, days | References |
|-------------|---------------|---------------|-----------------|--------------|-----------------------------------|-------------------------------|-----------------------------------------|-----------------------------------|------------|
| ChAdOx-1    |               |               |                 |              |                                   |                               |                                         |                                   |            |
| ChAdOx-1    | 11            | 9(82%)        | 22-49           | 9/11         | 8-107                             | 0/9                           | 1/5                                      | 5-18                | 2          |
| ChAdOx-1    | 5             | 4(80%)        | 32-54           | 4/5          | 10/70                             | 0/5                           | 2(3)/5                                  | 5-30                | 4          |
| ChAdOx-1    | 23            | 14(61%)       | 21-77           | 13/22        | 7/113                             | 1/23                          | NR                                      | 6-24                | 3          |
| ChAdOx-1    | 2             | 0(0%)         | 25-32           | 2/2          | 7/17                              | 0/1                           | 0/1                                      | 6-9                 | S1         |
| ChAdOx-1    | 1             | 1(100%)       | 55              | 0/1          | 30                                | 1/1                           | 0/1                                      | 10                  | 6          |
| ChAdOx-1    | 1             | 1(100%)       | 51              | 0/1          | 37                                | 0/0                           | 1/1                                      | 11                  | S5         |
| ChAdOx-1    | 1             | 1(100%)       | 60              | 0/1          | 5                                 | 0/1                           | 0/1                                      | 7                   | S2         |
| ChAdOx-1    | 3             | 3(100%)       | 22-46           | 3/3          | 60-92                             | 0/3                           | 0/3                                      | 4-17                | S3         |
| ChAdOx-1    | 1             | 1(100%)       | 54              | 1/1          | NR                                | 0/0                           | 3/3                                      | 12                  | S4         |
| ChAdOx-1    | 5             | 5(100%)       | 41-67           | 1/5          | 12-105                            | 0/5                           | 0/1                                      | 5-11                | S5         |
| ChAdOx-1    | 1             | 0(0%)         | 63              | 0/1          | 36                                | 0/1                           | (1)                                      | 20                  | S6         |
| ChAdOx-1    | 1             | 1(100%)       | 69              | 1/1          | 18                                | 0/1                           | 0/1                                      | 11                  | S7         |
| ChAdOx-1    | 1             | 0(0%)         | 50              | 1/1          | 15                                | 0/0                           | 0/0                                      | 11                  | S8         |
| ChAdOx-1    | 2             | 1(50%)        | 37-50           | 1/2          | 7-9                               | 0/2                           | 0/2                                      | 10                  | S9         |
| ChAdOx-1    | 7             | 4(57%)        | 24-53           | 4/7          | 8/1                               | 0/7                           | NR                                      | 6-20                | S10        |
| ChAdOx-1    | 2             | 0(0%)         | 25-32           | 2/2          | 19-30                             | 1/1                           | 0/1                                      | 6-9                 | S11        |
| ChAdOx-1    | 1             | 1(100%)       | 62              | 0/1          | 19                                | 0/1                           | 0/0                                      | 8                   | S12        |
| ChAdOx-1    | 1             | 1(100%)       | 30              | 1/1          | 56                                | 0/1                           | 0/1                                      | 8                   | S13        |
| ChAdOx-1    | 1             | 1(100%)       | 30              | 0/1          | 72                                | 0/1                           | 1/1                                      | 8                   | S14        |
| ChAdOx-1    | 4             | 3(75%)        | 29-50           | 1/4          | 24-110                            | 0/4                           | 0/1                                      | 7-20                | S15        |
| ChAdOx-1    | 1             | 1(100%)       | 41              | 1/1          | 36                                | 0/1                           | 0/0                                      | 7                   | S16        |
| ChAdOx-1    | 1             | 1(100%)       | 36              | 1/1          | 94                                | 0/0                           | 0/1                                      | 14                  | S17        |
| ChAdOx-1    | 1             | 0(0%)         | 51              | 1/1          | NR                                | 1/1                           | 1/1                                      | 6                   | S18        |
| ChAdOx-1    | 1             | 0(0%)         | 38              | 1/1          | 14                                | 0/1                           | 0/0                                      | 8                   | S19        |
| ChAdOx-1    | 1             | 0(0%)         | 50              | 1/1          | 15                                | 0/1                           | 0/0                                      | 7                   | S20        |
| ChAdOx-1    | 1             | 1(100%)       | 35              | 1/1          | 50                                | 0/1                           | 0/0                                      | 14                  | S21        |
| ChAdOx-1    | 1             | 0(0%)         | 54              | 1/1          | 34                                | 0/1                           | 0/0                                      | 21                  | S22        |
| ChAdOx-1    | 1             | 1(100%)       | 36              | 0/1          | 133                               | 0/1                           | 0/1                                      | 17                  | S23        |
| ChAdOx-1    | 1             | 0(0%)         | 44              | 0/1          | 6                                 | 0/1                           | 0/0                                      | 8                   | S24        |
| ChAdOx-1    | 1             | 0(0%)         | 27              | 1/1          | 68                                | 0/1                           | 0/0                                      | 2                   | S25        |
| ChAdOx-1    | 1             | 0(0%)         | 63              | 0/1          | 36                                | 0/1                           | 0/0                                      | 20                  | S26        |
| ChAdOx-1    | 1             | 0(0%)         | 30              | 1/1          | 37                                | 0/1                           | 0/0                                      | 7                   | S27        |
| ChAdOx-1    | 2             | 2(100%)       | 24-39           | 2/2          | 29-36                             | 0/2                           | 0/2                                      | 8-12                | S28        |
| ChAdOx-1    | 3             | 2(66.6%)      | 53-61           | 2/3          | 21-25                             | 0/3                           | 0/0                                      | 10-16               | S29        |
| Ad26.COV2.s |               |               |                 |              |                                   |                               |                                         |                                   |            |
| Ad26.COV2.s | 1             | 1(100%)       | 48              | 0/1          | 13                                | 1/1                           | 1/1                                      | 14                  | 1          |
| Ad26.COV2.s | 12            | 12(100%)      | 18-<600         | 7/12         | 8-127                             | 0/11                          | NR/6                                    | 6-15                | 12         |
| Ad26.COV2.s | 1             | 1(100%)       | 40              | 1/1          | 20                                | 0/1                           | 0/0                                      | 5                   | S30        |
| TOTAL       | 105           | 73(69.5%)     | 18-77           | 65/105(62%)  | 5-133                            | 5/92                          | 10(4)/41                                 | 2-30                | -          |

The reference numbers preceded by an S refer to references listed in the Online Supplementary Material. One patient had only thrombocytopenia. The patient was reported to have thrombotic thrombocytopenic purpura (TTP). One case included in this series was reported in reference S10. No thromboses were detected (possibly not a VITT). One of the cases did not have thrombosis. One case was initially treated with full dose low molecular weight heparin, with no apparent worsening, and was then changed to a non-heparin anticoagulant upon identification of positive anti PF4 antibodies. The platelet count was stated to be normal. Ages are reported as ranges, not individual. NR: not reported; PF4: platelet factor 4; VITT: vaccine-induced immune thrombotic thrombocytopenia.
The investigators showed that platelet activation was triggered by FcγRIIA stimulation, because an FcγRIIA-blocking antibody prevented this phenomenon. Given the absence of previous exposure to heparin, the authors suggested a condition resembling autoimmune HIT. More recently, in a preliminary report published in a non-peer-reviewed internet repository, the German group went on to suggest that the Ad vector and/or some protein components of the Vaxzevria vaccine activate platelets to release PF4 which then forms complexes with positively-charged PF4 which are recognized as neoantigens by B cells that then produce antibodies against these complexes. The resulting immune complexes activate platelets through FcγRIIa, triggering the release of additional PF4 and polyphosphates thereby initiating a positive feedback loop that leads to further platelet activation and consumption. Extracellular DNA in neutrophil extracellular traps binds PF4 and the resulting DNA/PF4 complexes further recruit anti-PF4 antibodies inducing massive Fcγ receptor-dependent activation of neutrophils, platelets, monocytes and endothelial cells leading to massive activation of coagulation and thrombosis. EDTA: ethylenediaminetetraacetic acid.

Figure 2. The autoimmune heparin-induced thrombocytopenia hypothesis. Vaccine components leaking into the bloodstream from the vaccination site (facilitated by ethylenediaminetetraacetic acid present in the vaccine) activate platelets to release platelet factor 4 (PF4). Vaccine constituents, likely polyanions or viral DNA, form complexes with positively-charged PF4 which are recognized as neoantigens by B cells that then produce antibodies against these complexes. The resulting immune complexes activate platelets through FcγRIIa, triggering the release of additional PF4 and polyphosphates thereby initiating a positive feedback loop that leads to further platelet activation and consumption. Extracellular DNA in neutrophil extracellular traps binds PF4 and the resulting DNA/PF4 complexes further recruit anti-PF4 antibodies inducing massive Fcγ receptor-dependent activation of neutrophils, platelets, monocytes and endothelial cells leading to massive activation of coagulation and thrombosis.
ity anti-PF4 antibodies. Furthermore, there is no evidence that the anti-PF4 antibodies isolated from patients with VITT cause thrombosis and thrombocytopenia in animal models.49,83 Finally, recent observations show that 1.2% to 8.0% of subjects receiving a first dose of Vaxzevria develop circulating anti-PF4 antibodies while the prevalence of VITT ranges from 0.0006% to 0.00125%.84,85

Other possible pathogenic mechanisms of vaccine-induced immune thrombotic thrombocytopenia

Very recently a preliminary report, published in a non-peer-reviewed repository, provided an interesting alternative potential pathogenic mechanism of VITT.86 COVID-19 is caused by SARS-CoV-2 which is a single-strand RNA virus that is translated and replicates only in the cytosol of infected cells in the absence of processes which are necessary when nuclear-encoded genes are transcribed, and in particular of mRNA splicing. Nuclear encoded genes have intronic sequences, thus their transcripts require splice reactions at consensus RNA sequences to eliminate them. When an Ad-vectored viral RNA sequence is administered the vector infects host cells, adenoviral DNA enters the nucleus and is then transcribed by the host transcription machinery. However, the viral piece of DNA deriving from the SARS-CoV-2 virus is not optimized to be transcribed into the nucleus and its open reading frame may thus be disrupted by arbitrary splice events. These splice events would produce shorter spike protein variants, including forms missing the C-terminal membrane anchor, thus leading to soluble circulating spike protein molecules. The soluble spike protein may cause a strong activation of endothelial cells expressing ACE2.87 Moreover, when the host immune system starts to produce antibodies against the spike protein, endothelial cells binding soluble spike would also be decorated by these antibodies, triggering a strong inflammatory reaction through antibody-dependent or complement-dependent cytotoxicity, thus eliciting VITT. With this hypothesis, the preferential involvement of cerebral
Adenovirus vaccines and thrombosis

veins could be explained by the non-unidirectional blood flow in these vessels due to the lack of venous valves, with prolonged residence time of the soluble spike protein in this district depending on body posture or when sleeping. The immunological part of this hypothesis is also in agreement with the apparent higher prevalence of VITT in young women, because they have stronger immune reactions than men and older people. To explain the rarity of VITT the authors hypothesized that only some individuals, due to specific major histocompatibility complex combinations, are not able to produce neutralizing anti-spike antibodies which would instead prevent the binding of soluble spike to endothelial ACE2 and its ominous consequences in most vaccine recipients. This hypothesis was partly validated by the identification through in silico analysis of potential splice sites in the AstraZeneca and Johnson&Johnson codon-optimized spike opening frames and by in vitro studies with HeLa cells showing that vaccine-transduced cells generate transcripts smaller than the full spike protein. It would also explain why VITT has not been reported with mRNA vaccines, which release their cargo mRNA directly into the host cells’ cytosol where it is translated into spike protein without undergoing splicing reactions. Finally, it would account for why the incidence of VITT seems to be lower with the Johnson&Johnson vaccine than with the AstraZeneca one, given that the latter carries more splice donor sequences than the former.

Additional hypotheses on the mechanisms triggering VITT include a genetically determined enhanced expression of FcγRIIa in susceptible subjects, an altered glycosylation state of IgG produced in response to vaccination in some individuals making these antibodies more reactive to platelet FcγRIIa, the leakage of the Ad vector into the circulation and/or the prior presence of cross-reactive antibodies to other coronaviruses forming immune complexes activating platelets. However, the hypothesis that VITT develops in subjects with previous, not apparent SARS-CoV-2 infection with prior circulating IgG antibodies against the spike protein able to activate platelet FcγRIIa should be excluded by the observation that most VITT subjects tested for previous or recent COVID-19 infections were negative. Excessive transcription of the spike protein, which would then activate platelets binding to ACE2, and vaccine-induced expression of the spike by megakaryocytes and platelets, leading to a thrombo-inflammatory storm, have also been proposed. Another hypothesis starts from the observation that both the ChAdOx1 and the Ad26-CoV2.S vaccines use polysorbate 80 as an excipient. Polysorbate 80 is a non-anionic surfactant that crosses the blood-brain barrier and enhances microparticle uptake by endothelial cells. Therefore leakage of Ad vector and polysorbate into the circulation and the spike protein produced by vaccination could preferentially localize in brain vessels triggering endothelial activation. However, considering that VITT usually develops at least 1 week after vaccination, it is very unlikely that circulating Ad vector or vaccine excipients would still be present in blood, making the alternative explanations, and in particular an immunological reaction, more likely.

Conclusive remarks

At least two Ad vector-based vaccines against SARS-CoV-2 have been associated with an excess rate of a special form of catastrophic thrombotic syndrome associated with thrombocytopenia of likely autoimmune origin, not observed so far with mRNA-based vaccines, suggesting that the vectors may play a role in eliciting it. Several elements of the Ad vectors and/or of vaccine composition may theoretically interact with platelets, the endothelium and the blood clotting system precipitating this rare complication. However, the exact sequence of events leading to the development of this syndrome and, most importantly, the reason why it evolves in only very few subjects without apparent predisposing factors remain to be clarified.

It is clear that our understanding of the pathogenesis of VITT is far from complete and that more mechanistic studies are required to clarify it and, it is hoped, to identify risk factors predictive of its development. What is quite likely is that the Ad vector-based vaccine triggers an immunological reaction which, for unknown reasons, in some rare subjects involves especially blood platelets, and possibly some peculiar vascular endothelial districts such as those of the cerebral and splanchnic veins, precipitating the catastrophic vaccine-induced autoimmune thrombocytopenia thrombosis syndrome. Awareness of this condition and the prompt identification/evaluation of affected patients may lead to successful treatment and recovery (Figure 3).

COVID-19 continues to be a serious global health problem and vaccination against SARS-CoV-2 is the most effective way of limiting illness and death due to the pandemic. Based on the current available information, and in light of the relative rarity of VITT, the benefits of vaccination clearly outweigh the potential risks. However, once the global pandemic begins to retreat, the relative importance of even small risks will increase, making it critically important to understand the mechanisms leading to this ominous thrombotic syndrome, to identify the prognostic factors for its development and to define the best management strategies.

Disclosures

No conflicts of interest to disclose.

Contributions

PG, VDS, AT, RM, SM and FR wrote the review article.

Acknowledgments

This work was supported in part by grants from Fondazione Cassa di Risparmio di Perugia (#19663 (2020.0508) and FISR 2020 (# 1049) to PG.
Adenovirus vaccines and thrombosis

Microbiol. 2020;5(10):1185-1191.

51. Hamada F, Aoki M, Akiyama T, Toyoshima K. Association of immunoglobulin G Fc receptor II with Src like protein-tyrosine kinase Fgr in neutrophils. Proc Natl Acad Sci U S A. 1993;90(15):6306-6309.

52. Ghazalpour FA, Bolen JB, Fleit HB. Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RI in monotypic TH-1 cells. J Biol Chem. 1994;269(12):8787-8884.

53. Kiener PA, Rankin BM, Burkhardt AL, et al. Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RI) on monotypic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J Biol Chem. 1995;260(32):24443-24448.

54. Nimmerjahn F, Ravetch JV. Fc receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.

55. Joshi T, Butchart JR, Tridandapani S. Fc receptor signaling in phagocytes. Int J Hematol. 2006;84(4):210-216.

56. Furuyama W, Marzi A, Carmody AB, et al. Heparin-induced thrombocytopenia: the interplay among antibody, spleen, and Fc receptor blood. 2000;96(13):4254-4260.

57. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, Bolenz SE. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor blood. 2000;96(13):4254-4260.

58. Calverley DC, Brass E, Hacker MR, et al. Potential role of platelet FcgammaRIIa in collagen-mediated platelet activation associated with atherosclerosis. Atherosclerosis. 2002;164(2):261-267.

59. Pamela S, Anna Maria L, Elena D et al. Heparin-induced thrombocytopenia: the role of platelets in genetic polymorphisms. Platelets. 2013;24(5):362-368.

60. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72-73.

61. Colloca S, Barnes E, Folgori A, et al. Virus vector derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(15):155ra22.

62. Obdulio GN, V’kovski V, Zettl F, Zimmer H, Thiel V, Summerfield A. No evidence for a systemic humoral immune response following simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(15):155ra22.

63. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2016;2(22):3360-3392.

64. Greinacher A, Farmer B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective of 405 patients. Thromb Haemost. 2005;94(1):132-135.

65. Greinacher A, Seileng K, Warkentin TE. Autoimmune heparin-induced thrombocytope-nia. J Thromb Haemost. 2017;15(11):2099-2114.

66. Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombocytopenia. Thromb Res. 2021;204:105860.

67. Favaloro EJ. Laboratory testing for suspect ed COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021;43(4):559-570.

68. Flattot S, Bartlett A, MacCalum P, et al. Evaluation of laboratory assays for antiplatelet factor 4 antibodies after ChAdOx1 nCoV-19 vaccination. J Thromb Haemost. 2021;19(2):2007-2013.

69. Cines DB, Russell JB. SARS-CoV2 Vaccine-induced immune thrombocytopenia. N Engl J Med. 2021;384(23):2254-2256.

70. Serevoll IH, Horvei KD, Ernstsen SL, et al. An observational study to identify the prevalence of thrombocytopenia and anti-FPA/polyanion antibodies in Norwegian health care workers after COVID-19 vaccina tion. J Thromb Haemost. 2021;19(7):1813-1818.

71. Thiele T, Ulm L, Holfreter S, et al. Frequency of positive anti-FPA/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021;138(4):299-303.

72. Kowarz E, Krutze L, Reis J, Bracharz S, Kochanek S, Marschalek R. Vaccine-induced Covid-19 spike open reading frame results in spike protein variant that may cause thromboembolic events in patients immunized with vector-based vacc ine. Research Square. 2021 May 26. [Epub ahead of print]

73. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128(9):1323-1326.

74. Chakraborty S, Gonzalez J, Edwards K. Proinflammatory IgG Fc receptor structures in patients with severe COVID-19. Nat Immunol. 2021;22(1):67-73.

75. Douxfils J, Favresse D, Dogné JM. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination. Thromb Res. 2021;203:163-171.

76. Shen S, Zhang J, Fang Y, et al. SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. J Hematol Oncol. 2021;29(1):72.

77. Millington-Burgess SL, Harper MT. A double-edged sword: antibody-mediated procoagulant platelets in COVID-19. Platelets. 2021;32(5):579-581.

78. Choi PH. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;385(2):e11.